Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multi-center, Open-label, Single-arm, Before and After Switch Study to Evaluate the Efficacy, Safety and Tolerability of Alemtuzumab in Paediatric Patients With Relapsing Remitting Multiple Sclerosis (RRMS) With Disease Activity on Prior Disease Modifying Therapy (DMT)

Trial Profile

A Multi-center, Open-label, Single-arm, Before and After Switch Study to Evaluate the Efficacy, Safety and Tolerability of Alemtuzumab in Paediatric Patients With Relapsing Remitting Multiple Sclerosis (RRMS) With Disease Activity on Prior Disease Modifying Therapy (DMT)

Status: Recruiting
Phase of Trial: Phase III

Latest Information Update: 03 Sep 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Alemtuzumab (Primary) ; Aciclovir; Cetirizine; Dexchlorpheniramine; Diphenhydramine; Glatiramer acetate; Histamine H1 receptor antagonists; Histamine H1 receptor antagonists; Histamine H2 receptor antagonists; Interferon beta; Interferon beta; Methylprednisolone; Paracetamol; Prednisolone; Ranitidine
  • Indications Multiple sclerosis
  • Focus Therapeutic Use
  • Acronyms LemKids
  • Sponsors Sanofi Genzyme
  • Most Recent Events

    • 19 Jun 2019 This trial has been suspended in Spain, according to European Clinical Trials Database.
    • 24 May 2019 This trial has been suspended in Portugal, according to European Clinical Trials Database.
    • 16 May 2019 This trial has been completed in Norway, according to European Clinical Trials Database.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top